Corvus Pharmaceuticals (NASDAQ:CRVS) issued its quarterly earnings results on Thursday. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.02), Bloomberg Earnings reports.
CRVS stock traded down $0.04 during midday trading on Friday, reaching $3.79. 316,121 shares of the company were exchanged, compared to its average volume of 307,385. The company has a current ratio of 12.39, a quick ratio of 12.39 and a debt-to-equity ratio of 0.03. Corvus Pharmaceuticals has a 1-year low of $3.22 and a 1-year high of $11.23. The company’s 50-day moving average price is $4.67.
CRVS has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, July 15th. Roth Capital initiated coverage on shares of Corvus Pharmaceuticals in a research note on Wednesday, May 29th. They issued a “buy” rating and a $6.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $9.19.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.
Featured Article: What is dollar cost averaging (DCA)?
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.